Radioterapia intraoperatoria de la mama con intrabeam, experiencia de la Unidad de Mastología del Hospital Italiano de Buenos Aires / Intraoperative radiotherapy of the breast with intrabeam, experience of the Mastology Unit of the Italian Hospital of Buenos Aires

Objetivo: La radioterapia intraoperatoria (IORT) es la radioterapia que se administra directamente al lecho tumoral. Existen varias modalidades de IORT. La empleada en nuestro centro es la que utiliza el dispositivo Intrabeam, el cual a través de rayos X de baja energía y un aplicador esférico que se adapta al lecho tumoral, permite la administración de la radiación a los tejidos con mayor riesgo de recidiva. Presentamos nuestra experiencia inicial de IORT con el dispositivo Intrabeam. Material y método: Se seleccionaron 51 pacientes con cáncer de mama para IORT con Intrabeam ® según protocolo TARGIT-A, desde febrero 2021 hasta mayo 2022. Los indicaciones fueron: pacientes mayores a 45 años, con tumores unifocales, < 3 cm de diámetro, luminales A o B, con axila clínica e imagenológicamente negativa. También se incluyen pacientes con carcinoma intraductal, de bajo grado o de grado intermedio. Resultados: La edad media fue de 66 años. Según el examen histológico definitivo, el tamaño tumoral promedio fue de 11.9 mm, con 95% de las pacientes con tumores menores a 2 cm. El 82.3% de nuestras pacientes completaron su tratamiento radiante sólo con la radioterapia intraoperatoria, pero en 9 casos (17.6%) fue necesario agregar radioterapia externa del volumen mamario. 10 pacientes (25.6%) tuvieron complicaciones, 2 casos fueron seromas que precisaron varias aspiraciones para su resolución. El resultado estético es muy bueno. Conclusiones: La IORT con Intrabeam es una alternativa segura y bien tolerada frente a la radioterapia externa en pacientes seleccionadas, con un buen resultado estético a corto plazo(AU)

Objetive: Intraoperative radiation therapy (IORT) is a radiation therapy delivered directly to the tumor bed. There are several modalities of IORT. The one used in our center is the one that uses the Intrabeam device, which through low-energy X-rays and a spherical applicator that adapts to the tumor bed, allows the administration of radiation to the tissues with the highest risk of recurrence. We present our initial experience with the Intrabeam device at our center. Material and method: From February 2021 to May 2022, 51 patients with breast cáncer were selected for IORT with Intrabeam® according to the TARGIT-A protocol. The indications were: patients older than 45 years, with unifocal tumors, < 3 cm in diameter, luminal A or B, with negative clinical and imaging axilla. Patients with intraductal, low-grade or intermediate-grade carcinoma were also included. Results: The mean age was 66 years. According to the definitive histological examination, the average tumor size was 11.9 mm, 95% of the patients with tumors smaller than 2 cm. 82.3% of our patients completed their radiant treatment with intraoperative radiotherapy alone, but in 9 cases (17.6%) it was necessary to add external radiotherapy of the breast volume. 10 patients (25.6%) had complications, 2 cases were seromas that required several aspirations for their resolution. The aesthetic result is very good. Conclusions: IORT with Intrabeam is a safe and well tolerated alternative versus external radiotherapy in selected patients and provides a good shortterm aesthetic result(AU)

INTRABEAM intraoperative radiotherapy in breast conserving surgery for early breast cancer / 中华内分泌外科杂志

Objective To evaluate the safety and feasibility of INTRABEAM in breast conserving surgery for early stage breast cancer.Methods Clinical data of 43 cases of early breast cancer undergoing INTRA-BEAM intraopetative radiotherapy from Jan.2013 to Dec.2014 were retrospectively analyzed.All cases underwent breast conserving surgery combined with 20 Gy INTRABEAM intraoperative radiotherapy.The postoperative incision,incidence of local complications and acute radiation injury were recorded after surgery.Breast recovery,the cosmetic effects,early overall survival,recurrence-free survival,and non-metastatic survival were followed up.Results All cases were given breast conserving surgery associated with INTRABEAM intraoperative radiotherapy (20 Gy),with median radiotherapy time of 31 mins ranging from 25 to 39 mins.Five cases underwent postoperative whole breast irradiation.Major early complications included incision infection (1 case),postoperative effusion (5 cases),radiation area skin pain (4 cases).The short-term follow-up survey showed that the satisfaction rate was 93.0％.The overall survival rate,recurrence free survival rate and metastasis free survival rate was 100％ respec tively.Conclusion Breast conseving surgery combined with INTRABEAM intraoperative radiotherapy for early breast cancer patients is safe and feasible.

Application and development of Intrabeam / 国际肿瘤学杂志

Intrabeam,a newly developed intraoperative radiotherapy in recent years,has many advantages such as accurate positioning,small size,easy to move and requiring a lower of protection.It is widely used in the treatment of breast cancer,colorectal cancer,lung cancer,bone metastases tumors and other malignancies.Intrabeam as a new way of intraoperative radiotherapy,is expected to provide more options for the treatment of a variety of neoplasms.